JOP20200327A1 - مركبات سيانوتريازول واستخداماتها - Google Patents
مركبات سيانوتريازول واستخداماتهاInfo
- Publication number
- JOP20200327A1 JOP20200327A1 JOP/2020/0327A JOP20200327A JOP20200327A1 JO P20200327 A1 JOP20200327 A1 JO P20200327A1 JO P20200327 A JOP20200327 A JO P20200327A JO P20200327 A1 JOP20200327 A1 JO P20200327A1
- Authority
- JO
- Jordan
- Prior art keywords
- compounds
- present
- cyanotriazole
- cyanotriazole compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
يوفر الاختراع الحالي مركب من الصيغة (I) أو ملح مقبول صيدلانياً منه: حيث يكون R1، R2، R3، وR4 كما تحدد هنا. يوفر الاختراع الحالي أيضاً استخدامات علاجية لهذه المركبات، على سبيل المثال ضد المثقبيات الأفريقية البشرية؛ تركيبات صيدلانية تشتمل على هذه المركبات، وتركيبات تشتمل على هذه المركبات مع عامل مساعد علاجي.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687045P | 2018-06-19 | 2018-06-19 | |
PCT/IB2019/055123 WO2019244049A1 (en) | 2018-06-19 | 2019-06-18 | Cyanotriazole compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200327A1 true JOP20200327A1 (ar) | 2020-12-15 |
Family
ID=67841115
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0327A JOP20200327A1 (ar) | 2018-06-19 | 2019-06-18 | مركبات سيانوتريازول واستخداماتها |
Country Status (21)
Country | Link |
---|---|
US (1) | US20220106296A1 (ar) |
EP (1) | EP3810598A1 (ar) |
JP (1) | JP2021528397A (ar) |
KR (1) | KR20210022646A (ar) |
CN (1) | CN112313217A (ar) |
AU (1) | AU2019291490B2 (ar) |
BR (1) | BR112020025538A2 (ar) |
CA (1) | CA3100954A1 (ar) |
CL (1) | CL2020003252A1 (ar) |
CR (1) | CR20200619A (ar) |
CU (1) | CU20200102A7 (ar) |
EA (1) | EA202190064A1 (ar) |
EC (1) | ECSP20080991A (ar) |
IL (1) | IL279483A (ar) |
JO (1) | JOP20200327A1 (ar) |
MA (1) | MA52977A (ar) |
MX (1) | MX2020013729A (ar) |
PE (1) | PE20210780A1 (ar) |
PH (1) | PH12020552186A1 (ar) |
SG (1) | SG11202012628XA (ar) |
WO (1) | WO2019244049A1 (ar) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115181060B (zh) * | 2022-08-19 | 2024-03-19 | 江苏禾裕泰化学有限公司 | 一种生产2-氨基-3-氯-5-三氟甲基吡啶的清洁生产工艺 |
CN116284772B (zh) * | 2023-02-09 | 2024-02-27 | 四川大学 | 一种联吡啶三唑共价有机聚合物及其制备方法和应用 |
CN116836111A (zh) * | 2023-09-01 | 2023-10-03 | 峰成医药科技(天津)有限公司 | 一种氟代吡啶的连续化合成方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
EP2790705B1 (en) * | 2011-12-15 | 2017-12-06 | Novartis AG | Use of inhibitors of the activity or function of pi3k |
US20170368034A1 (en) * | 2014-12-22 | 2017-12-28 | Glaxosmithkline Intellectual Property Development Limited | Thiotriazole compound and its use in parasitic protozoal infections |
-
2019
- 2019-06-18 MA MA052977A patent/MA52977A/fr unknown
- 2019-06-18 BR BR112020025538-6A patent/BR112020025538A2/pt not_active Application Discontinuation
- 2019-06-18 JP JP2020569931A patent/JP2021528397A/ja active Pending
- 2019-06-18 KR KR1020217001078A patent/KR20210022646A/ko unknown
- 2019-06-18 WO PCT/IB2019/055123 patent/WO2019244049A1/en unknown
- 2019-06-18 JO JOP/2020/0327A patent/JOP20200327A1/ar unknown
- 2019-06-18 EA EA202190064A patent/EA202190064A1/ru unknown
- 2019-06-18 MX MX2020013729A patent/MX2020013729A/es unknown
- 2019-06-18 CA CA3100954A patent/CA3100954A1/en active Pending
- 2019-06-18 US US17/253,737 patent/US20220106296A1/en not_active Abandoned
- 2019-06-18 CU CU2020000102A patent/CU20200102A7/es unknown
- 2019-06-18 EP EP19762468.7A patent/EP3810598A1/en not_active Withdrawn
- 2019-06-18 AU AU2019291490A patent/AU2019291490B2/en not_active Ceased
- 2019-06-18 SG SG11202012628XA patent/SG11202012628XA/en unknown
- 2019-06-18 PE PE2020002084A patent/PE20210780A1/es unknown
- 2019-06-18 CN CN201980040332.3A patent/CN112313217A/zh active Pending
- 2019-06-18 CR CR20200619A patent/CR20200619A/es unknown
-
2020
- 2020-12-15 EC ECSENADI202080991A patent/ECSP20080991A/es unknown
- 2020-12-16 IL IL279483A patent/IL279483A/en unknown
- 2020-12-16 CL CL2020003252A patent/CL2020003252A1/es unknown
- 2020-12-16 PH PH12020552186A patent/PH12020552186A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PE20210780A1 (es) | 2021-04-21 |
WO2019244049A1 (en) | 2019-12-26 |
MX2020013729A (es) | 2021-05-12 |
IL279483A (en) | 2021-01-31 |
BR112020025538A2 (pt) | 2021-03-16 |
JP2021528397A (ja) | 2021-10-21 |
CR20200619A (es) | 2021-01-21 |
CN112313217A (zh) | 2021-02-02 |
US20220106296A1 (en) | 2022-04-07 |
SG11202012628XA (en) | 2021-01-28 |
ECSP20080991A (es) | 2021-02-26 |
EA202190064A1 (ru) | 2021-03-29 |
AU2019291490B2 (en) | 2022-02-10 |
CU20200102A7 (es) | 2021-08-06 |
PH12020552186A1 (en) | 2021-06-07 |
MA52977A (fr) | 2021-04-28 |
AU2019291490A1 (en) | 2021-02-04 |
CL2020003252A1 (es) | 2021-07-09 |
CA3100954A1 (en) | 2019-12-26 |
KR20210022646A (ko) | 2021-03-03 |
EP3810598A1 (en) | 2021-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551821A1 (en) | Novel compounds | |
MX2018005890A (es) | Composiciones para tratar atrofia muscular espinal. | |
MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
MY194116A (en) | Pharmaceutical compounds | |
MX2022006783A (es) | Nuevos derivados de metilquinazolinona. | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة | |
MX2021012105A (es) | Compuestos de pirrol. | |
WO2018039077A8 (en) | Therapeutic compounds | |
PH12020551341A1 (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
MX2019011182A (es) | Combinacion de derivados de isoindolinona con sgi-110. | |
SG11201907945YA (en) | Azetidine derivative | |
PH12019502652A1 (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases | |
MX2022006104A (es) | Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma. | |
MX2022005951A (es) | Compuestos de pirrolotriazina que actuan como inhibidor de mnk. | |
JOP20220084A1 (ar) | مشتقات 5-أوكسا- 2- آزا سبيرو [3.4] أوكتان كناهضات لـ m4 | |
MX2021003232A (es) | Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa. | |
PH12019502261A1 (en) | Therapeutic or prophylactic agent for peripheral neuropathies | |
NZ764463A (en) | Heterocyclic compound and application thereof in medicine | |
MX2021014458A (es) | Compuestos triciclicos. | |
MX2022008487A (es) | Degradadores de smarca2-vhl. |